Freddy Heitz
Geneve, GE, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
NOX4 Inhibition Potentiates Immunotherapy by Overcoming Cancer-Associated Fibroblast-Mediated CD8 T-cell Exclusion from Tumors.
Journal: Cancer research
Published: October 10, 2019
Inhibition of host NOX1 blocks tumor growth and enhances checkpoint inhibitor-based immunotherapy.
Journal: Life science alliance
Published: December 06, 2018
NADPH oxidases as drug targets and biomarkers in neurodegenerative diseases: What is the evidence?
Journal: Free radical biology & medicine
Published: January 30, 2017
siRNA screen identifies QPCT as a druggable target for Huntington's disease.
Journal: Nature chemical biology
Published: August 14, 2014
Genetic targeting or pharmacologic inhibition of NADPH oxidase nox4 provides renoprotection in long-term diabetic nephropathy.
Journal: Journal of the American Society of Nephrology : JASN
Published: February 11, 2014
Fused 3-Hydroxy-3-trifluoromethylpyrazoles Inhibit Mutant Huntingtin Toxicity.
Journal: ACS medicinal chemistry letters
Published: July 03, 2013
NADPH oxidase 1 plays a key role in diabetes mellitus-accelerated atherosclerosis.
Journal: Circulation
Published: April 09, 2013
A phenotypic screening assay for modulators of huntingtin-induced transcriptional dysregulation.
Journal: Journal of biomolecular screening
Published: April 09, 2013
Renoprotective effects of a novel Nox1/4 inhibitor in a mouse model of Type 2 diabetes.
Journal: Clinical science (London, England : 1979)
Published: August 28, 2012
Showing 1-9 of 9
Last Updated: 09/26/2026